The Weekly Summay

Rand-PaulMarch 3rd – March 9th

In the general news, Russia continues to occupy the Crimea region of Ukraine. In the states, the February jobs report indicated 175,000 new jobs created.

In healthcare business news, earnings season wound down, with little news other than lawsuits being initiated against Medtronic (MDT) over InFuse.

On the data front, again there was little news other than Carmat’s first patient implanted with their artificial heart died.

From the FDA, Oxygen Bio (OXBT) shares spiked after the agency lifted a hold on Oxycyte to treat ischemic brain injury. Endo Pharmaceuticals (ENDP) long-acting injection testosterone drug Aveed was approved. Topical gel testosterones carry the added risk of infection others who come in contact with the user. In India, troubled Ranbaxy recalled its generic Lipitor. Lastly, Regeneron (REGN) shares sank as neurocognitive safety signals flared for large molecule cholesterol drug PCSK9, and the FDA asked for the companies to investigate.

This entry was posted in - The Weekly Summary. Bookmark the permalink.

Leave a Reply

Your email address will not be published.